Gilead Secures All Regulatory Approvals for Arcellx Acquisition, Extends Tender Offer

summarizeSummary

Gilead Sciences has obtained all necessary regulatory approvals for its acquisition of Arcellx, Inc. and has extended the tender offer expiration date to April 27, 2026.

check_boxKey Events

• All Regulatory Approvals Obtained

  Gilead Sciences has received all necessary regulatory approvals, including from Australian and Austrian competition authorities, for its acquisition of Arcellx. This removes a significant condition for the deal's completion.

• Tender Offer Extended

  The expiration date for the tender offer has been extended from April 24, 2026, to April 27, 2026, to allow additional time for shareholders to tender their shares.

• Tendered Shares Update

  As of April 16, 2026, approximately 10,271,823 shares, representing about 17.5% of Arcellx's outstanding shares, have been validly tendered.

auto_awesomeAnalysis

This amendment provides a critical update on the ongoing acquisition of Arcellx by Gilead Sciences. The confirmation that all required regulatory approvals have been secured significantly de-risks the transaction, moving it closer to completion. While the tender offer has been extended, this is a procedural step to allow more shares to be tendered, especially now that regulatory hurdles are cleared. The reported 17.5% tender rate indicates that a majority of shares still need to be tendered for the deal to close, but the removal of regulatory uncertainty is a major positive development for the acquisition.